Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vipoglanstat - Gesynta Pharma

Next Previous
Drug Profile

Vipoglanstat - Gesynta Pharma

Alternative Names: BI-1029539; GS-248; OX-MPI

Latest Information Update: 23 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biolipox
  • Developer Gesynta Pharma
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Endometriosis; Systemic scleroderma

Most Recent Events

  • 11 Mar 2026 Pharmacodynamics data from a preclinical studies in Endometriosis released by Gesynta Pharma
  • 15 Oct 2025 Phase-II clinical trials in Endometriosis in Italy, Poland, Romania, Bulgaria, Czech Republic, Hungary (PO) (NCT07260669)
  • 15 Oct 2025 Phase-II clinical trials in Endometriosis (In adults) in United Kingdom (PO) (NCT07260669)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top